Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
37 results about "Nicotinic Receptor Agonist" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Therapeutic combination for cognititon enhancement and psychotic disorders
InactiveUS20050215571A1Reduce the amount requiredGood effectBiocideNervous disorderAtypical antipsychoticPharmaceutical drug
This invention relates to combinations of an atypical antipsychotic, and a nicotinic receptor agonist or antagonist, kits containing such combinations, pharmaceutical compositions comprising such combinations, and methods of using such combinations to treat patients suffering from cognitive impairment disorders or psychotic disorders or conditions.
Owner:PFIZER INC
Pharmaceutical compositions for the treatment of CNS and other disorders
InactiveUS20060014750A1Ease of detectabilityEasy to prepareBiocideNervous disorderDiseaseΑ7 nicotinic receptor
The present invention relates to a method of treating disorders of the central nervous system (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant α7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant α7 nicotinic receptor agonist.
Owner:PFIZER INC
1,3,5-trisubstituted triazole derivative
ActiveUS20100240707A1Good curative effectBiocideNervous disorderAllosteric modulatorTriazole derivatives
The present invention relates to 2-[3-(2,2-Difluoro-benzo[1,3]dioxol-5-ylamino)-5-(2,6-dimethyl-pyridin-4-yl)-[1,2,4]triazol-1-yl]-N-ethyl-acetamide and analogues or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy.The invention particularly relates to a potent positive allosteric modulator of nicotinic acetylcholine receptors which have the capability of increasing the efficacy of nicotinic receptor agonists.
Owner:JANSSEN PHARMA NV
Positive modulators of nicotinic receptors
InactiveUS6861443B2Good curative effectRestore normal interneuronal communicationBiocideNervous disorderNicotinic Receptor AgonistReceptor for activated C kinase 1
The present invention relates to pharmaceutical compositions comprising a positive modulator of a nicotinic receptor agonist, said positive modulator having the capability to increase the efficacy of the said nicotinic receptor agonist.
Owner:ASTRAZENECA AB
Nicotinic receptor agonists for the treatment of inflammatory diseases
InactiveUS20050130990A1Minimize impactMinor side effectsBiocideOrganic chemistrySide effectAntiinflammatory drug
Owner:UNIV LAVAL
Pharmaceutical composition for the treatment of CNS and other disorders
InactiveUS6881734B2Ease of preparation and detectabilityGood metabolic stabilityBiocideNervous disorderDiseaseΑ7 nicotinic receptor
The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant α7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant α7 nicotinic receptor agonist.
Owner:PFIZER INC
Positive modulators of nicotinic receptor agonists
Compounds of Formula Iwherein R1, R2, R3, R4, R5, W and X as defined in the specification, enantiomers thereof, pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission. Compounds of the invention enhance the efficacy of agonists at nicotinic receptors.
Owner:ASTRAZENECA AB
Trisubstituted pyrazoles as acetylcholine receptor modulators
The present invention relates to 1-alkyl-3-aniline-5-aryl-pyrazole derivatives and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to Formula (I).The invention particularly relates to positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulator having the capability to increase the efficacy of nicotinic receptor agonists.
Owner:JANSSEN PHARMA NV
Nicotinic receptor agonists and analogues and derivatives thereof for the treatment of inflammatory diseases
InactiveUS20070249622A1Minimize impactMinor side effectsOrganic active ingredientsOrganic chemistrySide effectAntiinflammatory drug
Owner:UNIV LAVAL
Morpholinothiazoles as alpha 7 positive allosteric modulators
InactiveUS20120238561A1Antibacterial agentsOrganic active ingredientsAllosteric modulatorNicotinic Receptor Agonist
The present invention relates to morpholinothiazole derivatives and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulators having the capability to increase the efficacy of nicotinic receptor agonists.
Owner:JANSSEN PHARMA NV
Trisubstituted 1,2,4-triazoles
Owner:JANSSEN PHARMA NV
Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines
ActiveUS20120172354A1Good curative effectBiocideNervous disorderAllosteric modulatorNicotinic Receptor Agonist
The present invention relates to N-phenyl-1-(4-pyridinyl)-1H-pyrazol-3-amine derivatives and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to formula (I)Wherein R1, R2, R3, R4, R5, R6 have the meaning defined in the claims.The invention particularly relates to positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulator having the capability to increase the efficacy of nicotinic receptor agonists.
Owner:JANSSEN PHARMA NV
Trisubstituted 1,2,4 triazoles
The present invention relates to substituted 1-(alkyl)-3-aniline-5-aryl triazole derivatives and analogues or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to Formula (I).The invention particularly relates to potent positive allosteric modulators of nicotinic acetylcholine receptors which have the capability of increasing the efficacy of nicotinic receptor agonists.
Owner:JANSSEN PHARMA NV
Positive modulators of nicotinic receptor agonists
InactiveUS20050245595A1Enhance efficacy of agonistRestore normal interneuronal communicationBiocideNervous disorderEnantiomerNicotinic Receptor Agonist
Owner:ASTRAZENECA AB
Trisubstituted 1,2,4 triazoles
The present invention relates to 1-aryl-3-aniline-5-alkyl-1,2,4-triazole derivatives and analogues or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to Formula (I).The invention particularly relates to potent positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulator having the capability to increase the efficacy of nicotinic receptor agonists.
Owner:JANSSEN PHARMA NV
Azabenzoxazoles for the treatment of CNS disorders
InactiveUS20060166974A1Ease of preparation and detectabilityGood metabolic stabilityAntibacterial agentsBiocideDiseaseMedicine
The present invention relates to α7 nicotinic receptor agonists of formula I as described herein and to a method for treating disorders of the Central Nervous System (CNS) such as cognitive deficits in schizophrenia, by administering to a mammal an α7 nicotinic receptor agonist of formula I as shown herein.
Owner:PFIZER INC
Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
InactiveUS7091357B2Potent and selective antagonistic activityBiocideOrganic chemistryDiseaseStimulant
Owner:UNIV OF KENTUCKY RES FOUND
Capsaicin receptor agonists
InactiveCN1890223AReduced mechanical allodyniaReduced mechanical propertiesOrganic active ingredientsNervous disorderGABA-A Receptor AgonistsIn vivo
Owner:NEUROGEN
Nicotinic receptor agonists for the treatment of inflammatory diseases
ActiveUS20120022049A1Induce relaxationBiocideOrganic chemistryNicotinic Receptor AgonistPulmonary disease
Owner:UNIV LAVAL
Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
InactiveUS7307087B2Rapid onsetIncrease success rateBiocideNervous disorderNicotinic Acetylcholine Receptor AgonistNicotinic Receptor Agonist
This invention relates to use of the combined action of a nicotinic acetylcholine receptor agonist and a monoaminergic substance for the treatment of affective disorders, as well as to pharmaceutical compositions comprising these substances and chemical substances for use according to the invention.
Owner:SANIONA AS
Nicotinic receptor agonists for the treatment of inflammatory diseases
InactiveUS7601720B2Minimize impactMinor side effectsBiocideAntipyreticSide effectInflammatory bowel disease
This invention relates to the use of nicotine receptor agonists for treating inflammatory diseases, including a variety of pulmonary diseases. Such agonists have fewer side effects than other anti-inflammatory drugs, such as steroids. Moreover, these agonists can be used alone or in combination with other anti-inflammatory drugs to alleviate pulmonary diseases.
Owner:UNIV LAVAL
Antitussive compositions and methods
InactiveUS20170027918A1Suppressing coughPowder deliverySpray deliveryNicotinic Receptor AgonistStereochemistry
Disclosed herein are compositions which include nicotinic receptor agonists, specifically of the α7 nAChR subtype, and methods for suppressing cough.
Owner:ATTENUA INC
Nicotinic receptor agonists for the treatment of inflammatory diseases
This invention relates to the use of nicotine receptor agonists or analogs or derivatives thereof for treating inflammatory pulmonary diseases. The invention further relates to pharmaceutical compositions comprising nicotine receptor agonists or analogs or derivatives thereof. Novel compounds of formula wherein R1 ,R2 ,Xa and Ya are as defined herein are also provided.
Owner:UNIV LAVAL
Trisubstituted 1,2,4 triazoles
Owner:JANSSEN PHARMA NV
Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
InactiveUS20070265241A1Rapid onsetIncrease success rateBiocideNervous disorderNicotinic Acetylcholine Receptor AgonistNicotinic Receptor Agonist
This invention relates to use of the combined action of a nicotinic acetylcholine receptor agonist and a monoaminergic substance for the treatment of affective disorders, as well as to pharmaceutical compositions comprising these substances and chemical substances for use according to the invention.
Owner:OLSEN GUNNAR M +2
Nicotinic receptor agonists for the treatment of inflammatory diseases
InactiveCN101001843BOrganic active ingredientsOrganic chemistryNicotinic Receptor AgonistPulmonary disease
The present invention relates to the application of nicotinic receptor agonist or its analog or derivative in the treatment of inflammatory lung diseases. The invention further relates to pharmaceutical compositions comprising a nicotinic receptor agonist or an analogue or derivative thereof. Also provided are novel compounds of the general formula wherein R1, R2, Xa and Ya are as defined herein.
Owner:UNIV LAVAL
Nicotinic receptor agonists for the treatment of inflammatory diseases
InactiveUS20100227871A1Minimize impactMinor side effectsBiocideAntipyreticSide effectInflammatory bowel disease
This invention relates to the use of nicotine receptor agonists for treating inflammatory diseases, including a variety of pulmonary diseases. Such agonists have fewer side effects than other anti-inflammatory drugs, such as steroids. Moreover, these agonists can be used alone or in combination with other anti-inflammatory drugs to alleviate pulmonary diseases.
Owner:UNIV LAVAL
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com